Lung cancer is one of the most common and deadly cancers in the world. Millions of people are diagnosed with it every year, and many die because the disease is often detected late.

The biggest cause of lung cancer is smoking. Air pollution and workplace exposure to harmful substances also increase the risk. This makes lung cancer not only a medical problem, but also a public health problem.

The ideal solution is prevention. If doctors can identify people who are at high risk before cancer develops fully, they may be able to monitor them more closely or give preventive treatment.

A new scientific study has taken an important step in this direction.

A multinational team of researchers led by Charles Swanton of the Francis Crick Institute in London has identified a pattern of 14 proteins in blood plasma. They call it a “14-protein signature”. This signature may help predict who is at higher risk of being diagnosed with lung cancer years later.

This does not mean that a simple blood test for lung cancer prevention is already available in hospitals. The research is still at an early stage. But it is important because it shows that lung cancer may leave warning signs in the blood long before diagnosis.

To understand this discovery, we must first understand blood plasma.

Blood has different parts. One important part is plasma. Plasma is the liquid portion of blood. It carries proteins, hormones, nutrients, waste material, and many signals from different organs and tissues.

The full set of proteins present in blood plasma is called the plasma proteome. The large-scale study of proteins is called proteomics.

In simple words, blood plasma is like a report card of the body. If something is changing inside the lungs, liver, heart, immune system, or other organs, some of those changes may be reflected in the proteins present in the blood.

This is why scientists study blood plasma. A blood sample is easier to collect than a tissue sample. When scientists study disease-related signals from blood, it is sometimes compared to a liquid biopsy.

A traditional biopsy usually means taking a small piece of tissue from the body. A liquid biopsy tries to get disease information from blood. This is less invasive and can be repeated more easily.

In this study, researchers wanted to know whether blood proteins could give early warning signs of lung cancer.

For this, they used data from the U.K. Biobank. The U.K. Biobank is a large research project that follows around half a million volunteers over time. It stores biological samples and health information so that scientists can study why some people develop diseases and others do not.

For some volunteers, plasma protein profiles were available. The researchers used the data of about 48,000 volunteers to train a machine-learning model. They combined blood protein information with other details such as age, sex, smoking status, and future lung cancer diagnosis.

Machine learning helped researchers find patterns in the data. It worked like a pattern-detection tool. The model looked for protein combinations that were linked with later lung cancer diagnosis.

Through this process, the researchers identified 14 blood plasma proteins linked to lung cancer risk.

This is called a 14-protein signature.

A signature does not mean one single protein causes cancer. It means a pattern of proteins appears together in people who are more likely to develop lung cancer later. This pattern may show that the body, especially the lung environment, is already moving towards a high-risk state.

After finding the signature, researchers tested it on another group of people whose data had not been used to train the model. This is important because a model must not only work on the data it learned from. It must also work on new data.

In this test group, the model was able to identify more than 75% of future lung cancer cases. Many of these people were diagnosed years after their blood samples were taken. The median time to diagnosis was about 5.1 years.

This means the blood protein signature may detect risk signals more than five years before lung cancer is clinically diagnosed.

That is why the study is exciting.

But we must understand the meaning correctly. This signature does not say, “You definitely have lung cancer.” It says, “Your biological profile may show a higher risk, and you may need closer monitoring.”

This distinction is very important.

A risk prediction test is different from a cancer diagnosis test. Diagnosis means confirming that cancer is present. Risk prediction means estimating the possibility that cancer may develop in the future.

The study also found that the 14-protein signature appeared in other datasets. This included data from lifelong non-smokers. This suggests that the signature may not be useful only for smokers. It may also capture lung cancer risk linked to other causes.

However, smoking remains the biggest risk factor for lung cancer.

The study also gave an important clue about how lung cancer may develop.

Earlier, the same research team had suggested that air pollution can cause inflammation in the lungs. This inflammation may awaken dormant mutant cells. These are damaged cells that already carry mutations but have not yet become cancer.

The new study supports a similar idea.

Smoking may first create mutations in lung cells. These damaged cells may remain silent for some time. Later, inflammation caused by smoking, air pollution, or other environmental triggers may activate these cells. Over time, this process may lead to lung cancer.

So, lung cancer may develop in steps.

First, there is DNA damage or mutation.

Then, there is inflammation.

Then, damaged cells may start growing in an uncontrolled way.

Finally, cancer may appear.

This idea is important because it gives scientists a possible prevention target.

If inflammation helps cancer develop, then controlling inflammation in high-risk people may reduce the chance of cancer forming.

This is where the drug canakinumab enters the story.

Canakinumab is an anti-inflammatory drug made by Novartis. It is already approved in some countries for certain inflammatory disorders. It works by blocking a specific inflammatory pathway called IL-1 beta.

The researchers looked at an earlier clinical trial called CANTOS. This trial was not originally designed for lung cancer. It was designed to test whether canakinumab could reduce future heart problems in people who had already suffered a heart attack and still had inflammation.

Its effect on heart problems was modest. But when researchers looked back at the data, they noticed something interesting.

Among participants who had the 14-protein signature and received canakinumab, the risk of lung cancer was reduced by about 50%.

This suggests that canakinumab may possibly reduce lung cancer risk in selected high-risk people.

But this point must be handled carefully.

Canakinumab is not a general lung cancer prevention medicine today. Doctors cannot simply give it to people for lung cancer prevention based on this study alone.

Why?

Because the CANTOS analysis was retrospective. This means researchers looked back at old trial data to find a pattern. Retrospective analysis can give useful clues, but it is not the same as a new clinical trial designed specifically to test lung cancer prevention.

For canakinumab to be used for lung cancer prevention, new clinical trials will be needed. These trials must test whether the drug truly reduces lung cancer risk in people with the 14-protein signature.

There are also safety concerns.

Canakinumab can have serious side effects because it affects the immune system and inflammation pathways. If a drug reduces inflammation too much, it may increase the risk of infections or other complications.

There is also the issue of cost. Canakinumab is very expensive. In the United States, treatment can cost tens of thousands of dollars per year. It is also not easily available in countries like India.

So even if the idea is promising, it may not be practical for large-scale public health use unless safer and cheaper alternatives are found.

This is especially important for India.

India has many lung cancer risk factors: smoking, bidi use, air pollution, indoor pollution, industrial exposure, mining-related dust, construction dust, and occupational hazards. A blood-based early warning test could be useful in the future. But it will only help if it is affordable, accurate, validated in Indian populations, and connected to safe preventive care.

The 14-protein signature also needs more validation.

The study used data mainly from populations in the U.K., the U.S., and East Asia. Human populations are diverse. Genetics, environment, diet, smoking patterns, pollution exposure, and healthcare access differ across countries.

So scientists must test whether the same 14-protein signature works in many different populations, including India and other low- and middle-income countries.

Another important issue is false positives and false negatives.

A false positive means the test says someone is high risk, but that person never develops lung cancer. This could create anxiety, extra tests, and unnecessary treatment.

A false negative means the test says someone is low risk, but that person later develops lung cancer. This could create false reassurance.

So before any test becomes routine, scientists must know how accurate it is, who should be tested, how often they should be tested, and what doctors should do after a high-risk result.

This is why the discovery is exciting but not final.

The best way to understand this study is this: scientists may have found an early warning signal for lung cancer, but they still need to build the full medical system around it.

That system would need several steps.

First, the 14-protein signature must be validated across many populations.

Second, a reliable blood test must be developed to measure all 14 proteins.

Third, doctors must decide which people should be tested. For example, heavy smokers, former smokers, people with COPD, people with pulmonary fibrosis, or people with heavy occupational exposure may be considered.

Fourth, clinical trials must test whether drugs like canakinumab, or cheaper and safer alternatives, can actually prevent lung cancer in high-risk people.

Fifth, governments and healthcare systems must decide whether such testing and treatment can be made affordable.

Until then, the most important lung cancer prevention steps remain the same.

Do not smoke.

Quit smoking if you smoke.

Avoid second-hand smoke.

Reduce exposure to air pollution where possible.

Use protective equipment in dusty or hazardous workplaces.

Follow medical advice if you have chronic lung disease.

Seek medical attention for persistent cough, blood in sputum, unexplained weight loss, chest pain, or breathlessness.

The article’s main message is not that lung cancer has been solved. The main message is that scientists are moving closer to predicting lung cancer before it appears.

This is a major shift in thinking.

Traditionally, cancer medicine has focused on detecting and treating cancer after it develops. But the future may involve identifying people at high risk and preventing cancer before it becomes visible.

The 14-protein signature is important because it may help create that future.

It gives researchers a possible biological warning system. It also suggests that inflammation may be a key target in lung cancer prevention. And it opens the possibility that some existing drugs may be repurposed for cancer prevention in carefully selected people.

But caution is necessary.

This research is promising, not conclusive. It is a step forward, not a ready-made solution. The blood signature needs further validation. The drug needs proper trials. Safer and cheaper alternatives must be explored. And public health systems must ensure that such innovations do not remain available only to rich countries and rich patients.

In simple words, this discovery gives hope. It shows that lung cancer risk may be visible in the blood years before diagnosis. If future research confirms this, doctors may one day identify high-risk people early and prevent some cancers from developing.

That would be a major achievement in cancer medicine.

For now, the best conclusion is balanced: the 14-protein signature may become an important tool in the future, but today it remains a research finding. The safest and most proven prevention strategy is still to reduce smoking, pollution exposure, and occupational risks while improving early detection and healthcare access. :::